Financial Data and Key Metrics Changes - The company reported an 8% revenue growth for the quarter, with adjusted earnings per share increasing by 38% year over year [4][16] - Operating margin expanded by 450 basis points, driven by higher revenue and cost efficiencies [4][19] - Gross margin was 62.2%, a decline of 70 basis points year over year due to tariff impacts [18] Business Line Data and Key Metrics Changes - Healthcare revenue reached $371 million, representing an 8% growth [16] - Consumables grew by 1% this quarter, compared to a 20% growth in the same quarter last year [16] - Capital equipment and other revenues grew by 67% this quarter, rebounding from a 33% decline last year [16] Market Data and Key Metrics Changes - Incremental value of new contracts secured in the third quarter was $124 million, marking a 48% year-over-year increase [17] - Unrecognized contract revenue expected to be realized within the next 12 months was $507 million, a 17% year-over-year increase [17] Company Strategy and Development Direction - The company is focusing on three waves of growth: elevating commercial excellence, accelerating intelligent monitoring, and innovating wearables [9][10] - A strategic partnership with Philips was expanded, aiming to increase market share within Philips' installed base [5][32] - The company is investing in AI and machine learning to enhance its monitoring technologies and develop next-gen wearables [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the technology's performance, particularly in critical care settings [9] - The company anticipates a strong finish for the year, driven by continued demand and new customer installations [15] - Adjusted EPS guidance was raised, reflecting strong operational improvements and share repurchases [20][22] Other Important Information - The sale of Sound United's assets was completed, with net proceeds of $328 million used for debt repayment and share repurchases [19] - The company plans to provide more details on its product pipeline and long-term financial outlook at the upcoming Investor Day on December 3rd [69] Q&A Session Summary Question: What can be expected for the rest of the year and potential for further outperformance? - Management highlighted strong contracting performance and expected a strong finish in Q4, which would drive consumable growth [25] Question: How does the share buyback impact profitability? - The increase in EPS guidance was partly due to share buybacks and operational improvements, contributing to margin expansion [27] Question: What is the status of enhancing commercial excellence? - The company is focusing on enhancing resources for specialty categories and expects to see momentum pick up into next year [29] Question: Can you provide details on share gains with Philips? - The company noted that it still has a low market share within Philips' installed base and sees significant growth opportunities [32] Question: What is the outlook for consumables growth? - Management indicated that unusual year-over-year comparisons affected consumables growth, but they expect normalization and acceleration in Q4 [40][41] Question: What is the impact of the distributor model shift? - The shift to a distributor model in some international markets is expected to create a $6 million revenue headwind but is seen as a long-term growth strategy [42][44] Question: What is the broader capital allocation framework post-Sound United sale? - The company plans to focus on share repurchases and tuck-in technologies to augment its portfolio [63]

Economic Overview - Investors are concerned about the potential economic downturn due to new tariffs imposed by Trump, with Goldman Sachs raising its recession forecast from 20% to 35% [1][2] - Economists warn that these tariffs could lead to increased costs for businesses, a slowdown in hiring, and wage growth, prompting Wall Street firms to lower GDP growth projections [2] Medical Device Industry Outlook - The medical device industry is viewed as a stable investment during market volatility, with a promising long-term outlook despite short-term challenges such as tariffs and cost escalations [3] - Advancements in AI and predictive analytics are revolutionizing the medical device industry, enhancing diagnostics, patient monitoring, and personalized treatment [4] Company Highlights Masimo (MASI) - Masimo specializes in non-invasive patient monitoring systems and is benefiting from focused R&D efforts, with notable technologies like Measure-through Motion and Low Perfusion pulse oximetry [7] - MASI shares have increased by 1.4% year to date, outperforming the broader market, and the company is expected to report earnings growth of 20% in 2025 [8] Boston Scientific (BSX) - Boston Scientific is experiencing strength across its MedSurg and Cardiovascular lines, with strong demand and contributions from acquisitions driving growth [10] - BSX shares have risen 13.3% year to date, and the company is expected to report earnings growth of 13.6% in 2025 [12] Hims & Hers Health (HIMS) - Hims & Hers Health targets a $360 million U.S. total addressable market, focusing on mental health, weight loss, and dermatology, with over 2 million subscribers driving recurring revenues [15] - HIMS shares have surged 28.4% year to date, with an expected earnings growth of 133.3% in 2025 [16]